Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific
Advisory Board (SAB). The SAB, under the leadership of Carl June, M.D. as chairman, will provide strategic and scientific counsel to guide development of Ziopharm’s pipeline of immunotherapies to
treat patients with solid tumors.
The newly appointed members are:
- Adi Barzel, Ph.D., President of the Israeli Society of Gene and Cell Therapy; Senior Lecturer, Department of Biochemistry, School of NeuroBiology, Biochemistry and Biophysics, Tel Aviv University
- Gavin Dunn, M.D., Ph.D., Associate Professor of Neurological Surgery, Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine
- Matthew Porteus, M.D., Ph.D., Professor of Pediatrics (Stem Cell Transplantation), Stanford University
- Kole Roybal, Ph.D., Assistant Professor of Microbiology and Immunology, University of California, San Francisco; member of the Parker Institute for Cancer Immunotherapy Helen Diller Comprehensive Cancer Center
“We are pleased to welcome Drs. Barzel, Dunn, Porteus and Roybal as our scientific advisors to guide the development of our programs,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “Their extensive experience and knowledge of immunology will help advance Ziopharm’s immunotherapies toward our goal of treating any solid tumor. I look forward to collaborating closely with these notable experts.”
Dr. June added, “Each of our new members brings unparalleled experience in their respective fields, granting us the ability to be resourceful and strategic. I look forward to working with this team as we help guide the Company in advancing its pipeline of promising immunotherapies.”
Dr. Adi Barzel serves as the President of the Israeli Society of Gene and Cell Therapy and the Chair of the International Conference on Lymphocyte Engineering (ICLE). In 2016, he was appointed Senior Lecturer at the Department of Biochemistry and Molecular Biology at Tel Aviv University. In August 2014, Dr. Barzel co-founded the gene therapy start-up company LogicBio Therapeutics, which is developing durable cures for serious rare diseases based on the technology he developed during his postdoctoral research at Stanford University.